Xiilab Co., Ltd.

As of March 31, 2026, Xiilab Co., Ltd. carries a market capitalization of 41.66B, placing it among publicly traded companies globally. Its enterprise value stands at 19.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Xiilab Co., Ltd. has 9.38M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 3.52, and the price-to-book ratio stands at 1.78.

These figures are as of March 31, 2026. The EV/Sales ratio of 1.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.52B versus a market cap of 41.66B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Xiilab Co., Ltd. maintains a current ratio of 17.27, meaning it holds 17.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.40, indicating moderate leverage, while an interest coverage ratio of -76.00 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Xiilab Co., Ltd. posted a negative return on equity (ROE) of -25.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.84, reflecting losses generated across the asset base. The company generates approximately 161.84M in revenue per employee across its workforce of 65.50, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Xiilab Co., Ltd.'s stock has gained approximately 100.67% over the past 52 weeks. The 50-day moving average sits at 12,060.80, while the 200-day moving average is 8,036.30.

Over the twelve months ended March 31, 2026, Xiilab Co., Ltd. generated 10.60B in revenue and converted that into -4.04B in net income, yielding earnings per share of -481.53. EBITDA reached -3.16B, while operating income came in at -4.08B.

As of March 31, 2026, Xiilab Co., Ltd. holds 22.46B in cash and equivalents against 326.82M in total debt, resulting in a net debt position of -1.76B. Total book value stands at 23.41B, with working capital of 22.79B providing operational flexibility.

Xiilab Co., Ltd. produced -3.06B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -778.61M in capital expenditures, free cash flow totaled -3.84B - equivalent to -457.71 per share.

Over the twelve months ended March 31, 2026, Xiilab Co., Ltd. posted a gross margin of 22.47, reflecting its pricing power and cost economics. The operating margin of -38.52 and net profit margin of -38.12 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -10.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -43.29, meaning Xiilab Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Xiilab Co., Ltd.'s most recent stock split took place on July 1, 2025 with a 214:247 split ratio.

As of March 31, 2026, Xiilab Co., Ltd. has an Altman Z-Score of 10.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.